5 results
Primary Objectives:* To compare overall survival (OS) of patients who receive NKTR-102given once every 21 days (q21d) to patients who receive Treatment ofPhysician*s Choice (TPC) selected from the following list of seven singleagentintravenous…
Here, we aim to test whether disrupting reconsolidation by a noradrenergic *-blocker provides long-term relief of panic symptoms in burned-out employees.
Whether disrupting reconsolidation by a noradrenergic beta-blocker provides long-term relief from nicotine-addiction.
Whether disrupting reconsolidation by a noradrenergic β-blocker provides long-term relief of PTSD symptoms in traumatized healthcare workers.
Whether disrupting reconsolidation by a noradrenergic *-blocker provides long-term relief of PTSD symptoms in combat veterans.